Citation: Kim Lawson. Is there a role for melatonin in fibromyalgia?[J]. AIMS Molecular Science, 2019, 6(4): 73-86. doi: 10.3934/molsci.2019.4.73
[1] | Reham Ebrahim, Aya Abdelrazek, Hamed El-Shora, Abu Bakr El-Bediwi . Effect of ultraviolet radiation on molecular structure and photochemical compounds of Salvia hispanica medical seeds. AIMS Biophysics, 2022, 9(2): 172-181. doi: 10.3934/biophy.2022015 |
[2] | Mostean Bahreinipour, Hajar Zarei, Fariba Dashtestani, Jamal Rashidiani, Khadijeh Eskandari, Seyed Ali Moussavi Zarandi, Susan Kabudanian Ardestani, Hiroshi Watabe . Radioprotective effect of nanoceria and magnetic flower-like iron oxide microparticles on gamma radiation-induced damage in BSA protein. AIMS Biophysics, 2021, 8(2): 124-142. doi: 10.3934/biophy.2021010 |
[3] | Irina A. Zamulaeva, Kristina A. Churyukina, Olga N. Matchuk, Alexander A. Ivanov, Vyacheslav O. Saburov, Alexei L. Zhuze . Dimeric bisbenzimidazoles DB(n) in combination with ionizing radiation decrease number and clonogenic activity of MCF-7 breast cancer stem cells. AIMS Biophysics, 2020, 7(4): 339-361. doi: 10.3934/biophy.2020024 |
[4] | Derrick Lonsdale, Chandler Marrs . The potential of lipid soluble thiamine in the treatment of cancer. AIMS Biophysics, 2020, 7(1): 17-26. doi: 10.3934/biophy.2020002 |
[5] | Haliz Hussein, Hazhmat Ali, Zeki Mohamed, Majeed Mustafa, Khairi Abdullah, Asaad Alasady, Mayada Yalda . Thyroid function and hematological alterations in cardiac catheterization workers: a pre-post observational study on x-ray exposure. AIMS Biophysics, 2025, 12(1): 43-53. doi: 10.3934/biophy.2025004 |
[6] | Jaouhra Cherif, Anis Raddaoui, Ghofrane Ben Fraj, Asma Laabidi, Nada Souissi . Escherichia coli's response to low-dose ionizing radiation stress. AIMS Biophysics, 2024, 11(2): 130-141. doi: 10.3934/biophy.2024009 |
[7] | Francesca Ballarini, Mario P. Carante, Alessia Embriaco, Ricardo L. Ramos . Effects of ionizing radiation in biomolecules, cells and tissue/organs: basic mechanisms and applications for cancer therapy, medical imaging and radiation protection. AIMS Biophysics, 2022, 9(2): 108-112. doi: 10.3934/biophy.2022010 |
[8] | Etimad Alattar, Eqbal Radwan, Khitam Elwasife . Improvement in growth of plants under the effect of magnetized water. AIMS Biophysics, 2022, 9(4): 346-387. doi: 10.3934/biophy.2022029 |
[9] | Erma Prihastanti, Sumariyah Sumariyah, Febiasasti Trias Nugraheni . Increasing growth of monobulb garlic through the application of corona glow discharge plasma radiation and organic fertilizers. AIMS Biophysics, 2024, 11(1): 85-96. doi: 10.3934/biophy.2024006 |
[10] | Richard C Petersen . Free-radicals and advanced chemistries involved in cell membrane organization influence oxygen diffusion and pathology treatment. AIMS Biophysics, 2017, 4(2): 240-283. doi: 10.3934/biophy.2017.2.240 |
Let
The classical results of Lefschetz [13] say that the rational map associated to
There have been several improvements in this direction, by work of several authors, for instance [15] showed that for
Now, by adjunction, the canonical sheaf of
We succeed in this paper to find (respectively: conjecture) simple results for general such hypersurfaces.
Our work was motivated by a theorem obtained by the first author in a joint work with Schreyer [4] on canonical surfaces: if we have a polarization of type
The connection of the above result with the Lefschetz theorems is, as we already said, provided by adjunction, we have the following folklore result, a proof of which can be found for instance in [6] (a referee pointed out that the proof in the case of a principal polarization appears in 2.10 of [12], and that of course Green's proof works in general)
Lemma 1.1. Let
Let
If
$ (\theta_2, \dots, \theta_d,\frac{ \partial \theta_1}{ \partial z_1},\dots, \frac{ \partial \theta_1}{ \partial z_g}). $ |
Hence first of all the canonical map is an embedding if
This is our main result:
Theorem 1.2. Let
Then the canonical map
The first observation is: the hypothesis that we take a general such pair, and not any pair, is necessary in view of the cited result of [4].
The second observation is that the above result extends to more general situations, using a result on openness of birationality (this will be pursued elsewhere). This allows another proof of the theorem, obtained studying pull-backs of Theta divisors of hyperelliptic curves (observe that for Jacobians the Gauss map of the Theta divisor is a rational map, see [7] for a study of its degree).
Here we use the following nice result by Olivier Debarre [8]:
Theorem 1.3. Let
1. The branch divisor
2. The ramification divisor of
3. the local monodromies of the covering at the general points of
4. the Galois group of
The next question to which the previous result paves the way is: when is
An elementary application of the Severi double point formula [19] (see also [10], [2]) as an embedding obstruction, yields a necessary condition (observe that a similar argument was used by van de Ven in [20], in order to study the embeddings of Abelian varieties).
Theorem 1.4. Let
If the canonical map
$ d \geq g + 1. $ |
With some optimism (hoping for a simple result), but relying on the highly non-trivial positive result of the second author [6] concerning polarizations of type
Conjecture 1. Assume that
Then the canonical map
We end the paper discussing the conjecture.
We give first a quick outline of the strategy of the proof.
The first step 2.1 reduces to the case where the Pfaffian
Step 2.2 considers the particular case where
Step 2.3 shows that if
Step 2.4, the Key Step, shows that if
Step 2.5 finishes the proof, showing that, in each of the two possible cases corresponding to the subgroups of
We shall proceed by induction, basing on the following concept.
We shall say that a polarization type
Lemma 2.1. Assume that the polarization type
Proof. We let
There exists an étale covering
By induction, we may assume without loss of generality that all numbers
Then we have
Since by assumption
To contradict the second alternative, it suffices to show that the canonical system
Since then we would have as projection of the canonical map a rational map
$ F(x) = (x_0, x_1) \neq F(gx) = (x_0, \zeta x_1) , $ |
thereby separating the points of a general fibre.
Now, if there were only one non-zero eigenspace, the one for the eigenvalue
$ H^0 (X, {\mathcal{O}}_X (K_X)) = H^0 (X,\pi^* ( {\mathcal{O}}_{X'} (K_{X'})) = H^0 (X',\pi_* \pi^* ( {\mathcal{O}}_{X'} (K_{X'})) = $ |
$ = \oplus_1^p H^0 (X', {\mathcal{O}}_{X'} (K_{X'} + i \eta)), $ |
(here
But this is a contradiction, since the dimension
Here, we shall consider a similar situation, assuming that
We define
We consider the Gauss map of
$ f = \Psi \circ \phi, \ \phi : X {\rightarrow } Y , \ \Psi : Y {\rightarrow } P. $ |
The essential features are that:
(i)
(ii)
Either the theorem is true, or, by contradiction, we have a factorization of
In this case
That the canonical map of
We prove here a result which might be known (but we could not find it in [1]; a referee points out that, under the stronger assumption that
Lemma 2.2. The general divisor in a linear system
Proof. In this case of a polarization of type
We consider, as before, the inverse image
The curve
The double covering
Hence
Assume now that
Hence the hyperelliptic curves in
We shall use the Grauert-Remmert [11] extension of Riemann's theorem, stating that finite coverings
Remark 1. Given a connected unramified covering
(1) Then the group of covering trasformations
$ G : = Aut (X {\rightarrow } Y) \cong N_H / H, $ |
where
(2) The monodromy group
$ core({H}) = \cap_{ \gamma \in \Gamma} H^{ \gamma} = \cap_{ \gamma \in \Gamma} ( \gamma^{-1} H { \gamma} ), $ |
which is also called the normal core of
(3) The two actions of the two above groups on the fibre over
We have in fact an antihomomorphism
$ \Gamma {\rightarrow } Mon (X {\rightarrow } Y) $ |
with kernel
(4) Factorizations of the covering
We consider the composition of finite coverings
To simplify our notation, we consider the corresponding composition of unramified covering spaces of Zariski open sets, and the corresponding fundamental groups
$ 1 {\rightarrow } K_1 {\rightarrow } H_1 {\rightarrow } \Gamma_1. $ |
Then the monodromy group of the Gauss map of
We shall now divide all the above groups by the normal subgroup
$ 1 {\rightarrow } K {\rightarrow } H {\rightarrow } \Gamma, \ \Gamma = Mon (X^0 {\rightarrow } P^0). $ |
Since
● we have a surjection of the monodromy group
●
●
●
●
●
(I)
(II)
We consider now the case where there is a nontrivial factorization of the Gauss map
Define
$ 1 {\rightarrow } K {\rightarrow } \widehat{H} {\rightarrow } \Gamma, $ |
and set:
$ H' : = \widehat{H} \cap core({H}), \ H '' : = \widehat{H} / H' , \ H'' \subset \mathfrak S_{N}. $ |
Obviously we have
● in case (I), where
(Ia)
(Ib)
● in case (II), where
(IIa)
(IIb)
(IIc)
We first consider cases b) and c) where the index of
Lemma 2.3. Cases (b) and (c), where the degree
Proof. Observe in fact that
$ X {\rightarrow } Y {\rightarrow } P , \ X {\rightarrow } \Sigma {\rightarrow } P, $ |
hence we have that the degree of
$ (2p) N = m ( N \frac{2p}{m}). $ |
Consider now the respective ramification divisors
Since
Since the branch locus is known to be irreducible, and reduced, and
From the equality
To show that these special cases cannot occur, we can use several arguments.
For the case
For the case
$ Z: = \Sigma \times_P Y, $ |
so that there is a morphism of
If
Remark 2. Indeed, we know ([4]) that the monodromy group of
$ 1 {\rightarrow } K {\rightarrow } K_1 {\rightarrow } H {\rightarrow } \Gamma, $ |
where
At any rate, if
While, if
Excluded cases (b) and (c), we are left with case (a), where
$ H'' \subset \mathfrak S_{N-1} \Rightarrow \widehat{H} \subset H, $ |
equivalently
Here, we can soon dispense of the case
For the case where
$ r (\theta_i ) = \zeta^i \theta_i. $ |
If
$ r (s (\theta_i)) = s (r^{-1} (\theta_i)) = s ( \zeta^{-1} \theta_i) = \zeta^{-1} s ( \theta_i), $ |
hence we may assume without loss of generality that
$ s (\theta_i) = \theta_{-i}, \ -i \in {\mathbb{Z}}/p. $ |
It is then clear that
In the special case
$ \iota (z) = -z + \eta. $ |
If for a general deformation of
Theorem 3.1. Let
Assume moreover that
If
$ d \geq n + 2 = g + 1. $ |
Proof. Assume the contrary,
Observe that the pull back of the hyperplane class of
The Severi double point formula yields see ([10], also [5])
$ m^2 = c_n ( \Phi^* T_{ {\mathbb{P}}^{2n}} - T_X), $ |
where
By virtue of the exact sequence
$ 0 {\rightarrow } T_X {\rightarrow } T_A | X {\rightarrow } {\mathcal{O}}_X(X) {\rightarrow } 0, $ |
we obtain
$ m^2 = [(1 + X)^{2n+2} ]_n = {2n+2 \choose n} X^{n+1} \Leftrightarrow d (n+1)! = m = {2n+2 \choose n} . $ |
To have a quick proof, let us also apply the double point formula to the section of
In view of the exact sequence
$ 0 {\rightarrow } T_Y {\rightarrow } T_A | Y {\rightarrow } {\mathcal{O}}_Y(X)^{n-d+2} {\rightarrow } 0, $ |
we obtain
$ m^2 = [(1+X)^{n + d +1} X^{n-d+1} ]_n = {n + d + 1 \choose d-1} X^{n+1} $ |
equivalently,
$ d (n+1)! = m = {n + d + 1 \choose d-1} . $ |
Since, for
$ (n+1) (n+1)! = {2n+2 \choose n} \Leftrightarrow (n+2)! = {2n+2 \choose n+1} . $ |
We have equality for
$ (n+3)(n+2) = n^2 + 5n + 6 > 2(2n+3) = 4n + 6. $ |
We are done with showing the desired assertion since we must have
Recall Conjecture 1:
Conjecture 2. Assume that
Then the canonical map
The first observation is that we can assume
The second remark is that we have a partial result which is similar to lemma 2.1
Lemma 4.1. Assume that the polarization type
Proof. As in lemma 2.1 we reduce to the following situation: we have
Since by assumption
Recalling that
$ H^0 (X, {\mathcal{O}}_X (K_X)) = \oplus_1^p H^0 (X', {\mathcal{O}}_{X'} (K_{X'} + i \eta)), $ |
(here
Under our strong assumption
Already in the case of surfaces (
Were our conjecture too optimistic, then the question would arise about the exact range of validity for the statement of embedding of a general pair
the first author would like to thank Edoardo Sernesi and Michael Lönne for interesting conversations. Thanks to the second referee for useful suggestions on how to improve the exposition.
[1] |
Lawson K (2017) Emerging pharmacological strategies for the treatment of fibromyalgia. World J Pharmacol 6: 1–10. doi: 10.5497/wjp.v6.i1.1
![]() |
[2] | Borchers AT, Gershwin ME (2016) Fibromyalgia: a critical and comprehensive review. Clinic Rev Allerg Immunol 49: 100–151. |
[3] |
Clauw DJ (2014) Fibromyalgia: a clinical review. JAMA 311: 1547–1555. doi: 10.1001/jama.2014.3266
![]() |
[4] |
Üçeyler N, Zeller D, Kahn AK, et al. (2013) Small fibre pathology in patients with fibromyalgia syndrome. Brain 136: 1857–1867. doi: 10.1093/brain/awt053
![]() |
[5] | Wolfe F, Smythe HA, Yunus MB, et al. (1990) The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33: 160–172. |
[6] |
Macfarlane GJ, Kronisch C, Dean LE, et al. (2017) EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis 76: 318–328. doi: 10.1136/annrheumdis-2016-209724
![]() |
[7] |
Wolfe F, Clauw DJ, Fitzcharles MA, et al. (2010) The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 62: 600–610. doi: 10.1002/acr.20140
![]() |
[8] |
Queiroz LP (2013) Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep 17: 356. doi: 10.1007/s11916-013-0356-5
![]() |
[9] |
Sluka KA, Clauw DJ (2016) Neurobiology of fibromyalgia and chronic widespread pain. Neuroscience 338: 114–129. doi: 10.1016/j.neuroscience.2016.06.006
![]() |
[10] |
Fayed N, Garcia-Campayo J, Magallón R, et al. (2010) Localized 1H-NMR spectroscopy in patients with fibromyalgia: a controlled study of changes in cerebral glutamate/glutamine, inositol, choline, and N-acetylaspartate. Arthritis Res Ther 12: R134. doi: 10.1186/ar3072
![]() |
[11] |
Pyke TL, Osmotherly PG, Baines S (2017) Measuring glutamate levels in the brains of fibromyalgia patients and a potential role for glutamate in the pathophysiology of fibromyalgia symptoms: a Systematic Review. Clin J Pain 33: 944–954. doi: 10.1097/AJP.0000000000000474
![]() |
[12] |
Wood PB, Schweinhardt P, Jaeger E, et al. (2007) Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci 25: 3576–3582. doi: 10.1111/j.1460-9568.2007.05623.x
![]() |
[13] |
Vanecek J (1998) Cellular mechanisms of melatonin action. Physiol Rev 78: 687–721. doi: 10.1152/physrev.1998.78.3.687
![]() |
[14] |
Hardeland R, Cardinali DP, Srinivasan V, et al. (2011) Melatonin – A pleiotropic, orchestrating regulator molecule. Prog Neurobiol 93: 350–384. doi: 10.1016/j.pneurobio.2010.12.004
![]() |
[15] |
Ambriz-Tututi M, Rocha-González HI, Cruz SL, et al. (2009) Melatonin: a hormone that modulates pain. Life Sci 84: 489–498. doi: 10.1016/j.lfs.2009.01.024
![]() |
[16] |
Masruha M, de Souza Vieira DS, Minett TS, et al. (2008) Low urinary 6-sulfatoxymelatonin concentrations in acute migraine. J Headache Pain 9: 221–224. doi: 10.1007/s10194-008-0047-5
![]() |
[17] |
Masruha MR, Lin J, de Souza Vieira DS, et al. (2010) Urinary 6-sulfatoxymelatonin levels are depressed in chronic migraine and several comorbidities. Headache 50: 413–419. doi: 10.1111/j.1526-4610.2009.01547.x
![]() |
[18] |
Srinivasan V, Pandi-Perumal SR, Trahkt I, et al. (2009) Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int J Neurosci 119: 821–846. doi: 10.1080/00207450802328607
![]() |
[19] |
Srinivasan V, Lauterbach EC, Ho KY, et al. (2012) Melatonin in antinociception: its therapeutic applications. Curr Neuropharmacol 10: 167–178. doi: 10.2174/157015912800604489
![]() |
[20] |
Noseda R, Hernández A, Valladares L, et al. (2004) Melatonin-induced inhibition of spinal cord synaptic potentiation in rats is MT2 receptor-dependent. Neurosci Lett 360: 41–44. doi: 10.1016/j.neulet.2004.01.080
![]() |
[21] |
Laurido C, Pelissie T, Soto-Moyano R, et al. (2002) Effect of melatonin on rat spinal cord nociceptive transmission. Neuroreport 13: 89–91. doi: 10.1097/00001756-200201210-00021
![]() |
[22] |
Chen WW, Zhang X, Huang WJ. (2016) Pain control by melatonin: Physiological and pharmacological effects. Exp Ther Med 12: 1963–1968. doi: 10.3892/etm.2016.3565
![]() |
[23] |
Wilhelmsen M, Amirian I, Reiter RJ, et al. (2011) Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. J Pineal Res 51: 270–277. doi: 10.1111/j.1600-079X.2011.00895.x
![]() |
[24] |
Herrero JF, Laird JM, López-García JA (2000) Wind-up of spinal cord neurones and pain sensation: much ado about something? Prog Neurobiol 61: 169–203. doi: 10.1016/S0301-0082(99)00051-9
![]() |
[25] | Akerstedt T, Gillberg M, Wetterberg L (1982) The circadian covariation of fatigue and urinary melatonin. Biol Psychiatry 17: 547–554. |
[26] |
Pardini M, Cordano C, Benassi F, et al. (2014) Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study. Eur Neuropsychopharmacol 24: 939–944. doi: 10.1016/j.euroneuro.2014.02.010
![]() |
[27] |
San L, Arranz B (2008) Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry 23: 396–402. doi: 10.1016/j.eurpsy.2008.04.002
![]() |
[28] |
Ismail SA, Mowafi HA (2009) Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia. Anesth Analg 108: 1146–1151. doi: 10.1213/ane.0b013e3181907ebe
![]() |
[29] |
Nava F, Carta G (2001) Melatonin reduces anxiety induced by lipopolysaccharide in the rat. Neurosci Lett 307: 57–60. doi: 10.1016/S0304-3940(01)01930-9
![]() |
[30] |
Wan Q, Man HY, Liu F, et al. (1999) Differential modulation of GABAA receptor function by Mel1a and Mel1b receptors. Nat Neurosci 2: 401–403. doi: 10.1038/8062
![]() |
[31] |
Comai S, Gobbi G (2014) Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology. J Psychiatry Neurosci 39: 6–21. doi: 10.1503/jpn.130009
![]() |
[32] |
Bunney WE, Bunney BG (2000) Molecular clock genes in man and lower animals: possible implications for circadian abnormalities in depression. Neuropsychopharmacol 22: 335–345. doi: 10.1016/S0893-133X(99)00145-1
![]() |
[33] |
Quera Salva MA, Hartley S, Barbot F, et al. (2011) Circadian rhythms, melatonin and depression. Curr Pharm Des 17: 1459–1470. doi: 10.2174/138161211796197188
![]() |
[34] |
Srinivasan V, Brzezinski A, Pandi-Perumal SR, et al. (2011) Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedative-hypnotics? Prog Neuropsychopharmacol Biol Psychiatry 35: 913–923. doi: 10.1016/j.pnpbp.2011.03.013
![]() |
[35] | Rizzi M, Sarzi-Puttini P, Atzeni F, et al. (2004) Cyclic alternating pattern: a new marker of sleep alteration in patients with fibromyalgia? J Rheumatol 31: 1193–1199. |
[36] |
Wikner J, Hirsch U, Wetterberg L, et al. (1998) Fibromyalgia--a syndrome associated with decreased nocturnal melatonin secretion. Clin Endocrinol (Oxf) 49: 179–183. doi: 10.1046/j.1365-2265.1998.00503.x
![]() |
[37] | Press J, Phillip M, Neumann L, et al. (1998) Normal melatonin levels in patients with fibromyalgia syndrome. J Rheumatol 25: 551–555. |
[38] | Korszun A, Sackett-Lundeen L, Papadopoulos E, et al. (1999) Melatonin levels in women with fibromyalgia and chronic fatigue syndrome. J Rheumatol 26: 2675–2680. |
[39] | Klerman EB, Goldenberg DL, Brown EN, et al. (2001) Circadian rhythms of women with fibromyalgia. J Clin Endocrinol Metab 86: 1034–1039. |
[40] |
Senel K, Baygutalp F, Baykal T, et al. (2013) Melatonin levels in premenopausal women with fibromyalgia syndrome. Rheumatol Int 33: 1609–1610. doi: 10.1007/s00296-011-2315-y
![]() |
[41] | Pernambuco AP, Schetino LP, Viana RS, et al. (2015) The involvement of melatonin in the clinical status of patients with fibromyalgia syndrome. Clin Exp Rheumatol 33(Suppl 88): S14–19. |
[42] |
Caumo W, Hidalgo MP, Souza A, et al. (2019) Melatonin is a biomarker of circadian dysregulation and is correlated with major depression and fibromyalgia symptom severity. J Pain Res 12: 545–556. doi: 10.2147/JPR.S176857
![]() |
[43] |
Webb SM (1998) Fibromyalgia and melatonin: are they related? Clin Endocrinol (Oxf) 49: 161–162. doi: 10.1046/j.1365-2265.1998.00548.x
![]() |
[44] |
Musshoff U, Riewenherm D, Berger E, et al. (2002) Melatonin receptors in rat hippocampus: molecular and functional investigations. Hippocampus 12: 165–173. doi: 10.1002/hipo.1105
![]() |
[45] |
Citera G, Arias MA, Maldonado-Cocco JA, et al. (2000) The effect of melatonin in patients with fibromyalgia: a pilot study. Clin Rheumatol 19: 9–13. doi: 10.1007/s100670050003
![]() |
[46] |
Acuna-Castroviejo D, Escames G, Reiter RJ (2006) Melatonin therapy in fibromyalgia. J Pineal Res 40: 98–99. doi: 10.1111/j.1600-079X.2005.00278.x
![]() |
[47] |
Hussain SA, Al-Khalifa II, Jasim NA, et al. (2011) Adjuvant use of melatonin for treatment of fibromyalgia. J Pineal Res 50: 267–271. doi: 10.1111/j.1600-079X.2010.00836.x
![]() |
[48] |
de Zanette SA, Vercelino R, Laste G, et al. (2014) Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacol Toxicol 15: 40. doi: 10.1186/2050-6511-15-40
![]() |
[49] |
Castaño MY, Garrido M, Delgado-Adamez J, et al. (2018) Oral melatonin administration improves the objective and subjective sleep quality, increases 6-sulfatoxymelatonin levels and total antioxidant capacity in patients with fibromyalgia. J Appl Biomed 16: 186–191. doi: 10.1016/j.jab.2018.01.005
![]() |
[50] |
Castaño MY, Garrido M, Rodríguez AB, et al. (2019) Melatonin Improves Mood Status and Quality of Life and Decreases Cortisol Levels in Fibromyalgia. Biol Res Nurs 21: 22–29. doi: 10.1177/1099800418811634
![]() |
[51] |
Sánchez-Domínguez B, Bullón P, Román-Malo L, et al. (2015) Oxidative stress, mitochondrial dysfunction and, inflammation common events in skin of patients with Fibromyalgia. Mitochondrion 21: 69–75. doi: 10.1016/j.mito.2015.01.010
![]() |
[52] |
Fatima G, Das SK, Mahdi AA (2017) Some oxidative and antioxidative parameters and their relationship with clinical symptoms in women with fibromyalgia syndrome. Int J Rheum Dis 20: 39–45. doi: 10.1111/1756-185X.12550
![]() |
[53] |
Torres-Farfan C, Richter HG, Rojas-García P, et al. (2003) mt1 Melatonin receptor in the primate adrenal gland: inhibition of adrenocorticotropin-stimulated cortisol production by melatonin. J Clin Endocrinol Metab 88: 450–458. doi: 10.1210/jc.2002-021048
![]() |
[54] | Mahdi AA, Fatima G, Das SK, et al. (2011) Abnormality of circadian rhythm of serum melatonin and other biochemical parameters in fibromyalgia syndrome. Indian J Biochem Biophys 48: 82–87. |
[55] |
McLean SA, Williams DA, Harris RE, et al. (2005) Momentary relationship between cortisol secretion and symptoms in patients with fibromyalgia. Arthritis Rheum 52: 3660–3669. doi: 10.1002/art.21372
![]() |
[56] |
Bruno A, Micò U, Lorusso S, et al. (2013) Agomelatine in the treatment of fibromyalgia: a 12-week, open-label, uncontrolled preliminary study. J Clin Psychopharmacol 33: 507–511. doi: 10.1097/JCP.0b013e31829057ae
![]() |
[57] |
Calandre EP, Slim M, Garcia-Leiva JM, et al. (2014) Agomelatine for the treatment of patients with fibromyalgia and depressive symptomatology: an uncontrolled, 12-week, pilot study. Pharmacopsychiatry 47: 67–72. doi: 10.1055/s-0033-1363659
![]() |
[58] |
Finan PH, Goodin BR, Smith MT (2013) The association of sleep and pain: an update and a path forward. J Pain 14: 1539–1552. doi: 10.1016/j.jpain.2013.08.007
![]() |